Clinical evidence - Hemodynamics Transcatheter Aortic Valve Implantation (TAVI)

Clinical Evidence Demonstrates Industry-Leading Hemodynamics

The Medtronic transcatheter aortic valve with a self-expanding, supra-annular design delivers industry-leading hemodynamics. See the recently released clinical evidence on our newest generation TAVI device as well as longer-term hemodynamic performance out to 5 years on this proven platform:

Evolut Pro 29mm

Newest Generation Evolut PRO Study1

The Evolut PRO Study is a prospective, multicenter, non-randomized single-arm study. Primary safety endpoints were all-cause mortality and disabling stroke at 30 days. Primary efficacy endpoint was percentage of patients with none or trace aortic regurgitation at 30 days.

  • Study Status/Duration: 1 year outcomes reported/5-year follow-up
  • Sample Size: N = 60
  • Device: Evolut PRO TAV

SURTAVI (Intermediate Risk) Trial2

The SURTAVI Clinical Trial is a prospective, multinational, randomized clinical trial evaluating the CoreValve and Evolut R systems versus surgery in patients with symptomatic severe aortic stenosis at intermediate surgical risk.

  • Study Status/Duration: 1-year full Kaplan-Meier and 2-year Bayesian outcomes reported/10-year follow-up
  • Sample Size: N = 864 TAVI, 796 SAVR
  • Devices: CoreValve 84% / Evolut R 16% TAVs

ADVANCE Post-Market Study3

The CoreValve ADVANCE Study is a multicenter, prospective, single-arm observational study to evaluate safety and performance of the CoreValve system in a routine hospital setting.

  • Study Status/Duration: 5-year outcomes reported/5-year follow-up
  • Sample Size: N = 1,015
  • Devices: CoreValve, TAV

CoreValve Advance 5-years

Contact us


Lifeline cardiovascular technical support

Medtronic Academy

View more clinical data and access procedural resources.



Find additional feature information, educational resources, and tools.


Williams, as presented at 2018 ACC


Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. April 6, 2017;376(14):1321-1331.


Gerckens U, Tamburino C, Bleiziffer S, et al. Final 5-year clinical and echocardiographic results for treatment of severe aortic stenosis with a self-expanding bioprosthesis from the ADVANCE Study. Eur Heart J. September 21, 2017;38(36):2729-2738.